Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in researching, developing, and commercializing therapeutics to treat retinal diseases in the United States and international markets. Its lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy, including diabetic macular edema, as well as for macular edema due to retinal vein occlusion. The company's preclinical stage product candidate includes KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate conjugate to treat neovascular retinal diseases with an inflammatory component. Its early research pipeline includes KSI-601, a triplet inhibitor for the treatment of multifactorial retinal diseases, such as dry AMD and the neurodegenerative aspects of glaucoma. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is based in Palo Alto, California.
IPO Year: 2018
Exchange: NASDAQ
Website: kodiak.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/5/2024 | $3.00 | Neutral | H.C. Wainwright |
| 12/11/2023 | $2.00 | Sell | Goldman |
| 11/17/2023 | $7.00 → $12.00 | Equal Weight → Overweight | CapitalOne |
| 7/27/2023 | $15.00 → $4.00 | Buy → Neutral | UBS |
| 7/25/2023 | Buy → Neutral | Chardan Capital Markets | |
| 7/25/2023 | Neutral → Underweight | JP Morgan | |
| 7/24/2023 | Buy → Hold | Jefferies | |
| 7/24/2023 | $7.00 | Overweight → Equal Weight | CapitalOne |
| 11/15/2022 | $24.00 | Overweight | CapitalOne |
| 8/2/2022 | $6.00 | Neutral → Sell | Citigroup |
PALO ALTO, Calif., March 26, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that it will report fourth quarter and full-year 2023 financial results on Thursday, March 28, 2024. Management will host a conference call and live webcast to discuss recent business highlights and provide a corporate update at 4:30 p.m. Eastern Time on March 28, 2024. To access the webcast, please register at https://edge.media-server.com/mmc/p/q4jdxku4/. A live audio webcast of the event will be available on the "Events and Presentatio
PALO ALTO, Calif., Feb. 23, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD) today announced top-line results from its randomized, double-masked, active comparator-controlled Phase 2b/3 clinical trial evaluating the efficacy, durability and safety of KSI-301, a novel antibody biopolymer conjugate, in treatment-naïve subjects with neovascular (wet) age-related macular degeneration. The trial randomized 559 participants, approximately 80% of whom were enrolled in the United States. The study had two treatment arms: KSI-301 5mg on a flexible long-interval regimen and aflibercept 2mg on a fixed short-interval regimen. In the study, three monthly loading doses were administered to all subje
PALO ALTO, Calif., Nov. 14, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), today reported business highlights and financial results for the quarter ended September 30, 2024. "In the third quarter we hosted an Investor R&D Day in New York," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. "The Investor R&D Day webcast and presentation provide a comprehensive and up-to-date overview of where we stand today and where we are going – this is what I call 'Kodiak 2.0'. The video webcast includes scientific, clinical and commercial perspectives from key retina opinion leaders Dr. David Brown and Dr. Charles Wykoff. We encourage you to study these materials which are
PALO ALTO, Calif., Nov. 11, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that management will present at the following upcoming investor conferences. Members of the management team will also be available for one-on-one meetings. Jefferies London Healthcare Conference, November 21, 2024, 9:00 AM GMT (1:00 AM PT), London, UK7th Annual Evercore ISI HealthCONx Conference, December 3, 2024, 2:35 PM ET (11:35 AM PT), Coral Gables, FloridaA live webcast of both presentations will be available on the "Events and Pr
PALO ALTO, Calif., Oct. 14, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today its participation in a presentation and panel at Innovate Retina 2024 on October 17, 2024, in Chicago, Illinois. Presentation and Panel details are below: Presentation Title: Update on Antibody Biopolymer Conjugates: Optimizing Immediacy and DurabilityTime: 3:30 PM CTPresenter: Mark Barakat, M.D., FASRS, Clinical Assistant Professor of Ophthalmology, University of Arizona College of Medicine – Phoenix; Founder and Director of Research,
NEW YORK, Sept. 23, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), will host its Investor R&D Day today in New York. The event is from 10:30 am ET to 12:30 pm ET and can be accessed virtually at https://edge.media-server.com/mmc/p/2ff5vrm7. A link to the live webcast, replay and presentation slides of the event will be available on the "Events and Presentations" section of Kodiak's Investors & Media website at http://ir.kodiak.com/. A replay of the webcast will be available for a limited time following the event. The event will feature speakers from members of the Kodiak leadership team and the following leading retina specialist key opinion leaders (KOLs): David Brown, MD, Clinica
PALO ALTO, Calif., Sept. 17, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that it will host an Investor R&D Day with financial analysts and institutional investors on Monday, September 23, 2024, in New York City from 10:30 am ET to 12:30 pm ET. The event will feature presentations and roundtable discussions on Kodiak's science of durability, science of the enhanced formulation, timeline and other updates for the Company's active clinical pipeline, and the Company's expanding Antibody Biopolymer Conjugate Dr
PALO ALTO, Calif., May 29, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that management will present at the following upcoming investor conferences: Jefferies Healthcare Conference, June 6, 2024, 8:00 AM ET (5:00 AM PT), New York, New YorkGoldman Sachs 45th Annual Global Healthcare Conference, June 13, 2024, 8:00 AM ET (5:00 AM PT), Miami Beach, FloridaA live webcast of both presentations will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ and will remain
PALO ALTO, Calif., May 15, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), today reported business highlights and financial results for the quarter ended March 31, 2024. "We continue to make excellent operational progress with our three clinical programs of tarcocimab, KSI-501 and KSI-101, as well as on our duet and triplet research programs," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. "We are enrolling well in GLOW2 and remain on track to activate mid-year our next Phase 3 study DAYBREAK in wet AMD which is designed to investigate the efficacy, durability and safety of tarcocimab and KSI-501 in parallel against aflibercept. We also expect to initiate Ph
PALO ALTO, Calif., May 13, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that the first patients with diabetic retinopathy (DR) have been treated in the randomized double masked Phase 3 GLOW2 study of tarcocimab tedromer. GLOW2 is the second Phase 3 study of tarcocimab in diabetic retinopathy in which all patients on investigational therapy will receive tarcocimab on extended dosing intervals, including 6-month dosing for all patients. The GLOW2 study design mirrors the successful GLOW1 study in which tarcoc
Tarcocimab clinical and non-clinical data highlight strong 6-month efficacy profile in diabetic retinopathy patients and continued favorable safety profile.KSI-501 clinical and non-clinical data highlight multiple ascending dose safety, bioactivity and durability in treatment-naïve and treatment-experienced patients and next steps of Phase 3 development for KSI-501 and Phase 1b development for KSI-101.Novel small molecules and protein therapeutics highlight potential for targeted, high drug-antibody-ratio (DAR) conjugates built on Kodiak's ABC Platform.PALO ALTO, Calif., May 2, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, devel
Three clinical programs present diversified opportunities in and outside the existing anti-VEGF market and are being progressed toward Phase 3 value inflection points New Phase 3 GLOW2 study of tarcocimab in diabetic retinopathy actively recruiting Phase 1b study of KSI-101 planned for 2Q2024 with the goal of initiating dual pivotal studies in 2024 New Phase 3 DAYBREAK study in wet AMD to include KSI-501 and tarcocimab investigational groups versus aflibercept targeted to start recruitment mid-2024 following completion of FDA discussions Investor day to be scheduled after on-going regulatory interactions completedPALO ALTO, Calif., March 28, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NAS
10-Q - Kodiak Sciences Inc. (0001468748) (Filer)
8-K - Kodiak Sciences Inc. (0001468748) (Filer)
10-Q - Kodiak Sciences Inc. (0001468748) (Filer)
8-K - Kodiak Sciences Inc. (0001468748) (Filer)
8-K - Kodiak Sciences Inc. (0001468748) (Filer)
10-Q - Kodiak Sciences Inc. (0001468748) (Filer)
8-K - Kodiak Sciences Inc. (0001468748) (Filer)
ARS - Kodiak Sciences Inc. (0001468748) (Filer)
DEFA14A - Kodiak Sciences Inc. (0001468748) (Filer)
DEF 14A - Kodiak Sciences Inc. (0001468748) (Filer)
4 - Kodiak Sciences Inc. (0001468748) (Issuer)
4 - Kodiak Sciences Inc. (0001468748) (Issuer)
4 - Kodiak Sciences Inc. (0001468748) (Issuer)
4 - Kodiak Sciences Inc. (0001468748) (Issuer)
4 - Kodiak Sciences Inc. (0001468748) (Issuer)
4 - Kodiak Sciences Inc. (0001468748) (Issuer)
4 - Kodiak Sciences Inc. (0001468748) (Issuer)
4 - Kodiak Sciences Inc. (0001468748) (Issuer)
4 - Kodiak Sciences Inc. (0001468748) (Issuer)
4 - Kodiak Sciences Inc. (0001468748) (Issuer)
PALO ALTO, Calif., Sept. 17, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that it will host an Investor R&D Day with financial analysts and institutional investors on Monday, September 23, 2024, in New York City from 10:30 am ET to 12:30 pm ET. The event will feature presentations and roundtable discussions on Kodiak's science of durability, science of the enhanced formulation, timeline and other updates for the Company's active clinical pipeline, and the Company's expanding Antibody Biopolymer Conjugate Dr
SAN DIEGO--(BUSINESS WIRE)--Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the appointment of Julie Iwashita as the company’s Vice President of Clinical Operations. Ms. Iwashita brings more than 30 years of experience guiding global neurology and other clinical development programs through the U.S. Food and Drug Administration (FDA) and other global health authorities. “I am delighted to welcome Julie to Pipeline Therapeutics to spearhead our clinical development efforts,” said Carmine Stengone, President & CEO of Pipeline Therapeutics. “Julie’s extensive
SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)
SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)
SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)
SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)
SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)
SC 13G - Kodiak Sciences Inc. (0001468748) (Subject)
SC 13D/A - Kodiak Sciences Inc. (0001468748) (Subject)
SC 13D/A - Kodiak Sciences Inc. (0001468748) (Subject)
SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)
SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)
H.C. Wainwright initiated coverage of Kodiak Sciences with a rating of Neutral and set a new price target of $3.00
Goldman resumed coverage of Kodiak Sciences with a rating of Sell and set a new price target of $2.00
CapitalOne upgraded Kodiak Sciences from Equal Weight to Overweight and set a new price target of $12.00 from $7.00 previously
UBS downgraded Kodiak Sciences from Buy to Neutral and set a new price target of $4.00 from $15.00 previously
Chardan Capital Markets downgraded Kodiak Sciences from Buy to Neutral
JP Morgan downgraded Kodiak Sciences from Neutral to Underweight
Jefferies downgraded Kodiak Sciences from Buy to Hold
CapitalOne downgraded Kodiak Sciences from Overweight to Equal Weight and set a new price target of $7.00
CapitalOne initiated coverage of Kodiak Sciences with a rating of Overweight and set a new price target of $24.00
Citigroup downgraded Kodiak Sciences from Neutral to Sell and set a new price target of $6.00
Kodiak Sciences (NASDAQ:KOD) reported quarterly losses of $(0.82) per share which beat the analyst consensus estimate of $(1.07) by 23.36 percent.
Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that the first patients with diabetic retinopathy (DR) have been treated in the randomized double masked Phase 3 GLOW2 study of tarcocimab tedromer. GLOW2 is the second Phase 3 study of tarcocimab in diabetic retinopathy in which all patients on investigational therapy will receive tarcocimab on extended dosing intervals, including 6-month dosing for all patients. The GLOW2 study design mirrors the successful GLOW1 study in which tarcocimab-treated patients, over the 48-week study du
Tarcocimab clinical and non-clinical data highlight strong 6-month efficacy profile in diabetic retinopathy patients and continued favorable safety profile.KSI-501 clinical and non-clinical data highlight multiple ascending dose safety, bioactivity and durability in treatment-naïve and treatment-experienced patients and next steps of Phase 3 development for KSI-501 and Phase 1b development for KSI-101.Novel small molecules and protein therapeutics highlight potential for targeted, high drug-antibody-ratio (DAR) conjugates built on Kodiak's ABC Platform.PALO ALTO, Calif., May 2, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, devel
UBS analyst Eliana Merle maintains Kodiak Sciences (NASDAQ:KOD) with a Neutral and raises the price target from $3 to $5.
Gainers Aesthetic Medical Intl (NASDAQ:AIH) shares rose 14.0% to $0.52 during Wednesday's after-market session. The company's market cap stands at $24.9 million. Kineta (NASDAQ:KA) shares rose 8.46% to $0.58. The company's market cap stands at $6.3 million. Simulations Plus (NASDAQ:SLP) shares increased by 6.74% to $40.99. The market value of their outstanding shares is at $818.4 million. As per the news, the Q2 earnings report came out today. Bolt Biotherapeutics (NASDAQ:BOLT) shares moved upwards by 6.66% to $1.44. The company's market cap stands at $54.9 million. Eiger BioPharmaceuticals (NASDAQ:EIGR) shares increased by 6.66% to $1.76. The market value of their outstanding shares is
Barclays analyst Gena Wang maintains Kodiak Sciences (NASDAQ:KOD) with a Underweight and raises the price target from $2 to $3.
Gainers Avalo Therapeutics (NASDAQ:AVTX) shares increased by 364.8% to $22.08 during Friday's regular session. The market value of their outstanding shares is at $17.6 million. Nexalin Technology (NASDAQ:NXL) shares moved upwards by 83.33% to $1.43. The company's market cap stands at $10.4 million. Biodexa Pharmaceuticals (NASDAQ:BDRX) stock moved upwards by 81.6% to $1.56. The company's market cap stands at $6.6 million. Xilio Therapeutics (NASDAQ:XLO) shares moved upwards by 67.44% to $1.07. The company's market cap stands at $29.4 million. Mesoblast (NASDAQ:MESO) shares increased by 44.12% to $5.03. The company's market cap stands at $510.4 million. Regencell Bioscience (NASDAQ:RGC)
Shares of Kodiak Sciences Inc. (NASDAQ:KOD) fell sharply during Thursday’s session after the company reported a wider-than-expected fourth-quarter loss. Kodiak Sciences posted a quarterly loss of $1.13 per share, compared to market expectations for a loss of 77 cents per share. Kodiak Sciences shares dipped 19.9% to $5.97 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Avalo Therapeutics, Inc. (NASDAQ:AVTX) shares jumped 430% to $25.35 after the company announced it acquired a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio. The company also announced a private placement financing o
Gainers Avalo Therapeutics (NASDAQ:AVTX) stock rose 363.1% to $22.0 during Thursday's regular session. The company's market cap stands at $17.6 million. Xilio Therapeutics (NASDAQ:XLO) stock rose 133.95% to $1.5. The company's market cap stands at $41.1 million. Biodexa Pharmaceuticals (NASDAQ:BDRX) stock increased by 71.82% to $1.48. The market value of their outstanding shares is at $6.2 million. Mesoblast (NASDAQ:MESO) stock increased by 44.41% to $5.04. The company's market cap stands at $511.4 million. Ontrak (NASDAQ:OTRK) stock increased by 37.66% to $0.82. The company's market cap stands at $22.5 million. Nexalin Technology (NASDAQ:NXL) stock moved upwards by 35.85% to $1.06. Th